In a deciduous forest, differences in leaf phenology between juvenile and adult trees could result in juvenile trees avoiding canopy shade for part of the growing season. By expanding leaves earlier or initiating senescence later than canopy trees, juvenile trees would have some period in high light and therefore greater potential carbon gain. We observed leaf phenology of 376 individuals of 13 canopy tree species weekly over 3 years in a deciduous forest in east central Illinois, USA. Our objectives were: (1) to quantify for each species the extent of differences in leaf phenology between juvenile and conspecific adult trees; and (2) to determine the extent of phenological differences between juvenile Aesculus glabra Willd. and Acer saccharum Marsh. trees in understory and gap microhabitats. All species displayed phenological differences between life stages. For 10 species, bud break was significantly earlier, by an average of 8 days, for subcanopy individuals than for canopy individuals. In 11 species, completion of leaf expansion was earlier, by an average of 6 days, for subcanopy individuals than for canopy individuals. In contrast, there were no significant differences between life stages for start of senescence in 10 species and completion of leaf drop in nine species. For eight species, leaf longevity was significantly greater for subcanopy individuals than for canopy individuals by an average of 7 days (range = 4-10 days). Leaf phenology of subcanopy individuals of both Aesculus glabra and Acer saccharum responded to gap conditions. Leaf longevity was 11 days less in the understory than in gaps for Aesculus glabra, but 14 days more in the understory than in gaps for Acer saccharum. Therefore, leaf phenology differed broadly both between life stages and within the juvenile life stage in this community. A vertical gradient in temperature sums is the proposed mechanism explaining the patterns. Temperature sums accumulated more rapidly in the sheltered understory than in an open elevated area, similar to the canopy. Early leaf expansion by juvenile trees may result in a period of disproportionately higher carbon gain, similar to gains made during summer months from use of sun flecks.

To date, there are no biomarkers for major depressive disorder (MDD) treatment response in clinical use. Such biomarkers could allow for individualized treatment selection, reducing time spent on ineffective treatments and the burden of MDD. In search of such a biomarker, multisite pretreatment and early-treatment (1 week into treatment) structural magnetic resonance (MR) images were acquired from 184 patients with MDD randomized to an 8-week trial of the selective serotonin reuptake inhibitor (SSRI) sertraline or placebo. This study represents a large, multisite, placebo-controlled effort to examine the association between pretreatment differences or early-treatment changes in cortical thickness and treatment-specific outcomes. For standardization, a novel, robust site harmonization procedure was applied to structural measures in a priori regions (rostral and caudal anterior cingulate, lateral orbitofrontal, rostral middle frontal, and hippocampus), chosen based on previously published reports. Pretreatment cortical thickness or volume did not significantly associate with SSRI response. Thickening of the rostral anterior cingulate cortex in the first week of treatment was associated with better 8-week responses to SSRI (p = 0.010). These findings indicate that frontal lobe structural alterations in the first week of treatment may be associated with long-term treatment efficacy. While these associational findings may help to elucidate the specific neural targets of SSRIs, the predictive accuracy of pretreatment or early-treatment structural alterations in classifying treatment remitters from nonremitters was limited to 63.9%. Therefore, in this large sample of adults with MDD, structural MR imaging measures were not found to be clinically translatable biomarkers of treatment response to SSRI or placebo.

(2015) A pilot randomised controlled trial to compare changes in quality of life for participants with early diagnosis dementia who attend a "Living Well with Dementia" group compared to waiting-list control. Aging and Mental Health, 19 (6 Disclaimer UWE has obtained warranties from all depositors as to their title in the material deposited and as to their right to deposit such material. UWE makes no representation or warranties of commercial utility, title, or fitness for a particular purpose or any other warranty, express or implied in respect of any material deposited.UWE makes no representation that the use of the materials will not infringe any patent, copyright, trademark or other property or proprietary rights. UWE accepts no liability for any infringement of intellectual property rights in any material deposited but will remove such material from public view pending investigation in the event of an allegation of any such infringement. PLEASE SCROLL DOWN FOR TEXT.Living well with dementia groups: a pilot RCT Living well with dementia groups: a pilot RCT 3 AbstractObjective. The aim of this paper is to report a pilot study in which participants who had recently received a diagnosis of dementia were randomised to either a 10 week group intervention or to a waiting list control.Method. Memory Clinic staff with limited previous experience of group therapy were trained to lead a ten week group therapy intervention called "Living Well with Dementia". Fifty-eight participants, all of whom had received a diagnosis of Alzheimer's disease, Vascular or Lewy body dementia within the previous 18 months, were randomised to receive either the intervention or treatment as usual (waiting list control). Data collection occurred at baseline, within two weeks of the intervention finishing and at 10 week follow-up.Results. The study met its recruitment targets, with a relatively low attrition rate for the intervention arm. The acceptability of the intervention and research methods were examined qualitatively and are reported on elsewhere. For the primary outcome measure of quality of life (Qol-AD) and secondary outcome, self-esteem there was some evidence of improvement in the intervention group compared to the control group. There was, also, evidence of a reduction in cognitive functioning in the treatment group compared to the control. Such reported differences should be treated with caution because they are obtained from a pilot and not a definitive studyConclusions. This pilot study succeeded in collect data to inform a future definitive cost effectiveness clinical trial of Living Well with Dementia Group Therapy.

No abstract

Major depressive disorder (MDD) is a serious, heterogeneous disorder accompanied by brain-related changes, many of which are still to be discovered or refined. Arterial spin labeling (ASL) is a neuroimaging technique used to measure cerebral blood flow (CBF; perfusion) to understand brain function and detect differences among groups. CBF differences have been detected in MDD, and may reveal biosignatures of disease-state. The current work aimed to discover and replicate differences in CBF between MDD participants and healthy controls (HC) as part of the EMBARC study. Participants underwent neuroimaging at baseline, prior to starting study medication, to investigate biosignatures in MDD. Relative CBF (rCBF) was calculated and compared between 106 MDD and 36 HC EMBARC participants (whole-brain Discovery); and 58 MDD EMBARC participants and 58 HC from the DLBS study (region-of-interest Replication). Both analyses revealed reduced rCBF in the right parahippocampus, thalamus, fusiform and middle temporal gyri, as well as the left and right insula, for those with MDD relative to HC. Both samples also revealed increased rCBF in MDD relative to HC in both the left and right inferior parietal lobule, including the supramarginal and angular gyri. Cingulate and prefrontal regions did not fully replicate. Lastly, significant associations were detected between rCBF in replicated regions and clinical measures of MDD chronicity. These results (1) provide reliable evidence for ASL in detecting differences in perfusion for multiple brain regions thought to be important in MDD, and (2) highlight the potential role of using perfusion as a biosignature of MDD.